By Kamran Zamanian, Ph.D, and Scott McInnes, iData Research Inc.

The market for European orthopedic biomaterials (OB) has undergone dramatic changes over the last two years. Prices, quantities sold, and competitors have been in an almost constant state of flux. While quantities sold are marginally increasing, ASPs (average sales prices) are being driven down by an increase in competition.

Included in our analysis are the markets for bone morphogenetic proteins (BMPs), hyaluronic acid viscosupplementation injections, bone graft substitutes, and autologous chondrocyte implantations (ACIs).

While the entire OB market has been in a state of contraction over the past few years, especially following Olympus’s exit from the BMP market, it is expected to…